Showing 1,161 - 1,180 results of 101,635 for search '(( 5 ((((nm decrease) OR (a decrease))) OR (mean decrease)) ) OR ( 12 men decrease ))', query time: 1.48s Refine Results
  1. 1161

    <i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

    Published 2017
    “…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
  2. 1162
  3. 1163

    Progesterone decreased Henkel 100-induced responses in a dose-dependent manner in the OE of female mice. by Ninthujah Kanageswaran (683924)

    Published 2016
    “…<p>(A) Representative submerged EOG esponses to Henkel 100 (1:5,000) were recorded from the surface of the septum from female mouse OE. …”
  4. 1164
  5. 1165
  6. 1166
  7. 1167
  8. 1168

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  9. 1169

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  10. 1170

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  11. 1171

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  12. 1172
  13. 1173
  14. 1174

    Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

    Published 2013
    “…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”
  15. 1175
  16. 1176
  17. 1177
  18. 1178
  19. 1179
  20. 1180

    Blocking TNF or IL-6 decreases HIV-1 replication significantly in a dose dependent manner. by Shahin Ranjbar (66979)

    Published 2013
    “…Blocking TNF (at 2 ug/ml or 5 ug/ml) or IL-6 (5 ug/ml) significantly decreased virus replication (*, p<0.05) as compared to the same concentrations of an IgG<sub>1</sub> control antibody. …”